For early cancer detection, think of EasyCheck360®
Early cancer screening is crucial because it increases the chances of detecting cancer at an initial stage when it is more likely to respond to treatment, improving survival rates, and enabling potentially curative options. Early-stage detection often allows for less aggressive treatments, reduces healthcare costs, and enhances the quality of life of patients by catching the disease before it progresses to advanced, harder-to-treat stages.
EasyCheck360 is a non-invasive blood test designed to detect cancer early by identifying Circulating tumor Cells (CTCs). These cells are only found in individuals with cancer and are not present in people with non-cancerous conditions, making this test highly accurate. EasyCheck360® can detect CTCs in almost all types of cancer, including early stages (Stage 0, I, and II), in both men and women.
By providing reliable results, this test helps your doctor make timely and informed decisions about your health, giving you the best chance for early diagnosis and potentially curative treatment.
Usual invasive tissue biopsy for cancer diagnosis can be cumbersome, carries risks for patients, and sometimes is inaccurate too.
Trublood offers a risk-free, accurate, and cost-effective alternative to traditional biopsies for detecting solid tumors and brain tumors. It is a safe method that remains effective even when primary or metastatic cancers are undetectable by conventional means, providing crucial diagnostic insights without invasive procedures.
Trublood can avoid pain and anxiety related to traditional biopsies with a non-invasive solution to detect colorectal cancer and cancers of the CNS, lung, breast, pancreas, and prostate.
Advanced Cancer? Explore Precision Treatment Options
Cancer is a genetic disease.Every individual is unique, and so is their cancer biology. However, the conventional 'standard of care' approaches are based on population studies, which disregard the unique genetic landscape and complex metabolic dynamics of the tumor.
As a result, the patients are at risk of failed therapies or aggressive relapse. It is, thus, imperative that the genetic architecture of the tumor is studied comprehensively before deciding the treatment plan, which has to be personalized to the individual patient and his/her disease.
Datar offers advanced and comprehensive tumor profiling tests that analyze cellular and genetic data to provide personalized and actionable treatment recommendations. These tests ensure that every treatment plan is tailored to your specific cancer profile.
Exacta is a comprehensive, in-depth, integrative, cellular, and molecular tumor analysis that parses millions of data points to present actionable vulnerabilities of the tumor for effective treatment strategies.
ExploreCellDx-Tissue is a comprehensive tissue-based molecular profiling assay for solid tumors that uses advanced next-generation sequencing (NGS) to identify clinically relevant genomic alterations, including targeted therapy and immunotherapy biomarkers. It is the only US FDA-cleared comprehensive genomic profiling assay available from India, with an approved scope covering validated biomarkers within the intended-use framework, along with an expanded laboratory-developed test (LDT) scope for broader molecular insights and emerging biomarkers to support precision oncology decision-making.
ExploreProxceq™ is a one-of-a-kind, tissue-based tumor profiling solution designed to provide a deeper understanding of each patient’s cancer and support more personalized treatment strategies
ExplorePinaka is a non-invasive blood test that detects Circulating tumor Cells (CTCs) from your bloodstream, providing crucial insights to guide cancer treatment. Using advanced techniques like immunocytochemistry (ICC) and FISH, Pinaka analyses key biomarkers to match you with the most effective therapies. With just a quick blood draw, this test offers accurate and reliable information comparable to traditional tumor tissue testing, making cancer care safer and more personalized.
ExploreChemoscale provides blood-based analysis of tumor cells to guide you on which chemotherapy drug will work for you.
Explore
For non-invasive cancer monitoring, think Cancertrack.
Explore Cancertrack™
It eliminates the need for radiation, hospitalisation, anaesthesia, or painful biopsies, providing a safer and more efficient way to track how your cancer responds to therapy and to monitor further progression.
Explore
By combining personalized tumor-informed detection and broad tumor-agnostic profiling, it helps your doctor monitor your health, detect relapse early, and tailor treatment to your unique needs. This test provides ongoing insights to ensure better outcomes and timely care.
Explore